Day One Biopharmaceuticals Inc (DAWN)

$7.50 +0.01 (0.13%)
Market Cap 767.22M
Revenue (ttm) 131.16M
Net Income (ttm) -95.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -72.81%
Debt to Equity Ratio 0.00
Volume 928,900
Avg Vol 1,236,932
Day's Range N/A - N/A
Shares Out 102.43M
Stochastic %K 46%
Beta -1.26
Analysts Strong Sell
Price Target $24.55

Company Profile

Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 484 0899
Address:
1800 Sierra Point Parkway, Suite 200, Brisbane, United States
Bio_Invest101
Bio_Invest101 Oct. 27 at 8:07 PM
$DAWN Another ADC related deal signed today https://www.fiercebiotech.com/biotech/gsk-pens-357m-pact-french-biotech-preclinical-prostate-cancer-adc
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 27 at 4:39 PM
$DAWN Red 🤣..... now back to All Time Low
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 27 at 4:28 PM
$DAWN $XBI Every DAY 💩🤣🤣🤣 never seen a 100% CHAPTER 11 company 👍🏻👍🏻
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 27 at 2:54 PM
$DAWN delisting now this criminal company
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 27 at 1:44 PM
$DAWN $XBI Ultra Short activ
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 27 at 11:05 AM
$DAWN $XBI at Ultra high $DAWN Ultra Low...... this will crash hard fast to All Time Low 🤣💩
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 27 at 8:26 AM
$DAWN Short extrem every DAY
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 27 at 5:33 AM
$DAWN 🥳🥳
0 · Reply
Bio_Invest101
Bio_Invest101 Oct. 26 at 11:12 PM
$DAWN M&A Deal No. 10 in very hot Oct https://www.prnewswire.com/news-releases/avidity-biosciences-enters-into-agreement-to-be-acquired-by-novartis-ag-302594703.html $IRWD
0 · Reply
Bio_Invest101
Bio_Invest101 Oct. 24 at 4:34 PM
$DAWN $IRWD Another deal today No.9 What a red hot Oct M&A market https://www.fiercepharma.com/pharma/roches-chugai-strikes-200m-ma-deal-take-over-igan-asset-several-asian-countries
0 · Reply
Latest News on DAWN
Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025

Oct 21, 2025, 8:30 AM EDT - 6 days ago

Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025

Day One Biopharmaceuticals: Bear Case Priced In, But Bull Case Is Not (Rating Upgrade)

Aug 7, 2025, 10:26 PM EDT - 2 months ago

Day One Biopharmaceuticals: Bear Case Priced In, But Bull Case Is Not (Rating Upgrade)

Day One Biopharmaceuticals, Inc. (DAWN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 9:19 PM EDT - 2 months ago

Day One Biopharmaceuticals, Inc. (DAWN) Q2 2025 Earnings Call Transcript

Day One Reports Second Quarter 2025 Financial Results and Corporate Progress

Aug 5, 2025, 4:00 PM EDT - 2 months ago

Day One Reports Second Quarter 2025 Financial Results and Corporate Progress

Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025

Jul 22, 2025, 8:30 AM EDT - 3 months ago

Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025

Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

Jun 10, 2025, 8:30 AM EDT - 4 months ago

Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301

Jun 4, 2025, 8:59 PM EDT - 5 months ago

Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301

Day One Biopharmaceuticals, Inc. (DAWN) Q1 2025 Earnings Call Transcript

May 6, 2025, 10:12 PM EDT - 6 months ago

Day One Biopharmaceuticals, Inc. (DAWN) Q1 2025 Earnings Call Transcript

Day One Reports First Quarter 2025 Financial Results and Corporate Progress

May 6, 2025, 4:01 PM EDT - 6 months ago

Day One Reports First Quarter 2025 Financial Results and Corporate Progress

Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

Apr 22, 2025, 8:30 AM EDT - 6 months ago

Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity

Apr 10, 2025, 11:51 PM EDT - 7 months ago

Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity

Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 7:02 AM EST - 8 months ago

Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call Transcript

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

Feb 25, 2025, 4:05 PM EST - 8 months ago

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

Feb 11, 2025, 8:30 AM EST - 9 months ago

Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)

Jan 7, 2025, 11:31 AM EST - 10 months ago

Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)

Day One Biopharmaceuticals: Sales Figures In The Crosshairs

Dec 25, 2024, 7:31 AM EST - 10 months ago

Day One Biopharmaceuticals: Sales Figures In The Crosshairs

Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 17, 2024, 8:30 AM EST - 11 months ago

Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

Nov 20, 2024, 4:30 PM EST - 1 year ago

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 18, 2024, 8:30 AM EST - 1 year ago

Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference

Day One Biopharmaceuticals, Inc. (DAWN) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 10:57 PM EDT - 1 year ago

Day One Biopharmaceuticals, Inc. (DAWN) Q3 2024 Earnings Call Transcript

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

Oct 30, 2024, 4:01 PM EDT - 1 year ago

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024

Oct 16, 2024, 8:30 AM EDT - 1 year ago

Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024

Day One Reports Second Quarter 2024 Financial Results and Corporate Progress

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Day One Reports Second Quarter 2024 Financial Results and Corporate Progress

Day One Announces Oversubscribed $175.0 Million Private Placement

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Day One Announces Oversubscribed $175.0 Million Private Placement

Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor

Jul 25, 2024, 12:58 AM EDT - 1 year ago

Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

Jun 18, 2024, 8:30 AM EDT - 1 year ago

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

Day One Announces Sale of Priority Review Voucher for $108 Million

May 30, 2024, 8:30 AM EDT - 1 year ago

Day One Announces Sale of Priority Review Voucher for $108 Million

Day One Reports First Quarter 2024 Financial Results and Corporate Progress

May 6, 2024, 4:30 PM EDT - 1 year ago

Day One Reports First Quarter 2024 Financial Results and Corporate Progress

Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

Apr 23, 2024, 3:56 PM EDT - 1 year ago

Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

Feb 26, 2024, 4:30 PM EST - 1 year ago

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects

Feb 1, 2024, 10:07 AM EST - 1 year ago

Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects

Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 19, 2023, 8:00 AM EST - 2 years ago

Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

Nov 17, 2023, 7:00 AM EST - 2 years ago

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

Day One Reports Third Quarter 2023 Financial Results and Corporate Progress

Nov 6, 2023, 4:30 PM EST - 2 years ago

Day One Reports Third Quarter 2023 Financial Results and Corporate Progress

Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Day One Biopharmaceuticals: NDA Filing Decision Is An Inflection Point To Watch

Sep 15, 2023, 3:21 PM EDT - 2 years ago

Day One Biopharmaceuticals: NDA Filing Decision Is An Inflection Point To Watch

Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Sep 11, 2023, 9:02 PM EDT - 2 years ago

Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Day One Reports Second Quarter 2023 Financial Results and Corporate Progress

Aug 7, 2023, 4:30 PM EDT - 2 years ago

Day One Reports Second Quarter 2023 Financial Results and Corporate Progress

Diving Into Day One Biopharmaceuticals

Jul 23, 2023, 4:43 AM EDT - 2 years ago

Diving Into Day One Biopharmaceuticals

Day One Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jun 12, 2023, 8:00 AM EDT - 2 years ago

Day One Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Day One Announces Pricing of Public Offering of Common Stock

Jun 6, 2023, 10:31 PM EDT - 2 years ago

Day One Announces Pricing of Public Offering of Common Stock

Day One Announces Proposed Public Offering of Common Stock

Jun 6, 2023, 4:01 PM EDT - 2 years ago

Day One Announces Proposed Public Offering of Common Stock

Cancer drugmakers rise as industry meet fuels investor interest

Jun 5, 2023, 10:59 AM EDT - 2 years ago

Cancer drugmakers rise as industry meet fuels investor interest

EVAX GTHX

Day One Biopharmaceuticals shares jump 23% on positive results for glioma treatment

Jun 5, 2023, 8:09 AM EDT - 2 years ago

Day One Biopharmaceuticals shares jump 23% on positive results for glioma treatment

Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma

Jun 4, 2023, 12:45 PM EDT - 2 years ago

Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma

Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference

May 30, 2023, 8:00 AM EDT - 2 years ago

Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference

CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2023, 8:30 PM EDT - 2 years ago

CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2023, 5:00 PM EDT - 2 years ago

Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Day One Reports First Quarter 2023 Financial Results and Corporate Progress

May 1, 2023, 9:00 AM EDT - 2 years ago

Day One Reports First Quarter 2023 Financial Results and Corporate Progress

Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 26, 2023, 9:31 AM EDT - 2 years ago

Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Bio_Invest101
Bio_Invest101 Oct. 27 at 8:07 PM
$DAWN Another ADC related deal signed today https://www.fiercebiotech.com/biotech/gsk-pens-357m-pact-french-biotech-preclinical-prostate-cancer-adc
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 27 at 4:39 PM
$DAWN Red 🤣..... now back to All Time Low
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 27 at 4:28 PM
$DAWN $XBI Every DAY 💩🤣🤣🤣 never seen a 100% CHAPTER 11 company 👍🏻👍🏻
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 27 at 2:54 PM
$DAWN delisting now this criminal company
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 27 at 1:44 PM
$DAWN $XBI Ultra Short activ
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 27 at 11:05 AM
$DAWN $XBI at Ultra high $DAWN Ultra Low...... this will crash hard fast to All Time Low 🤣💩
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 27 at 8:26 AM
$DAWN Short extrem every DAY
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 27 at 5:33 AM
$DAWN 🥳🥳
0 · Reply
Bio_Invest101
Bio_Invest101 Oct. 26 at 11:12 PM
$DAWN M&A Deal No. 10 in very hot Oct https://www.prnewswire.com/news-releases/avidity-biosciences-enters-into-agreement-to-be-acquired-by-novartis-ag-302594703.html $IRWD
0 · Reply
Bio_Invest101
Bio_Invest101 Oct. 24 at 4:34 PM
$DAWN $IRWD Another deal today No.9 What a red hot Oct M&A market https://www.fiercepharma.com/pharma/roches-chugai-strikes-200m-ma-deal-take-over-igan-asset-several-asian-countries
0 · Reply
Bio_Invest101
Bio_Invest101 Oct. 24 at 3:54 PM
$IRWD Deal No 8 in Oct alone https://www.prnewswire.com/news-releases/lilly-to-acquire-adverum-biotechnologies-302593482.html $DAWN
0 · Reply
tradernava
tradernava Oct. 23 at 4:27 PM
$DAWN why lack luster performance with respect to market's relative strength?
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 23 at 3:45 PM
$DAWN complete destroying is near my Spartaner only delisting is the key.... this Pos fraud succcer will RIP HARD TO CHAPTER 11.... Do it $XBI $MCRB $ITRM more scam to Short
2 · Reply
I_am_Sparta
I_am_Sparta Oct. 23 at 1:58 PM
$DAWN Zero incoming IMMINENT 👍🏻😃
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 22 at 6:43 PM
$DAWN last Call.... here is it... Zero, CHAPTER 11 and delisting $XBI
0 · Reply
Bio_Invest101
Bio_Invest101 Oct. 22 at 4:45 PM
$IRWD Deal No 7 in Oct. super hot https://www.businesswire.com/news/home/20251021765122/en/Hologic-to-be-Acquired-by-Blackstone-and-TPG-for-up-to-%2479-per-Share $DAWN
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 22 at 4:36 PM
$DAWN $XBI we say heidschi bumbeidschi booooooom booooooooom to Zero $BMNR $IREN
0 · Reply
Bio_Invest101
Bio_Invest101 Oct. 22 at 4:30 PM
$DAWN Our EU partner is busy doing deals This is No. 6 deal overall in Oct. lots of M&A happening in 4th Q https://www.fiercebiotech.com/biotech/ipsen-writes-check-worth-eu1b-acquire-next-gen-cancer-biotech $IRWD
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 22 at 3:13 PM
$DAWN when fking delisting 🥱🥱🥱 i will destroy this criminal scam Pos fraud company to Ultra delisting
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 22 at 2:28 PM
$UPST boooooooooom Zero incoming IMMINENT $BMNR $DAWN Short everything TO ZERO
0 · Reply
I_am_Sparta
I_am_Sparta Oct. 22 at 1:44 PM
$DAWN Pos fraud...when delisting 🤣💩👈🏻 Red or Red 🤣💩💩👈🏻👈🏻🤡
0 · Reply
Redposition
Redposition Oct. 22 at 1:00 PM
$DAWN Time is near : $25.
1 · Reply